

REGISTER BY 31ST JANUARY AND SAVE \$400
REGISTER BY 28TH FEBRUARY AND SAVE \$200
REGISTER BY 31ST MARCH AND SAVE \$100



SMi proudly present their 4th annual conference and exhibition...

Pre-Filled Syringes East Coast

The Colonnade, Boston, MA, USA



26TH - 27TH
APRIL
2017

**Opportunities and innovations in pre-filled technology
developments**



HIGHLIGHTS IN 2017:

- Analyse and forecast market trends for prefills with **Pfizer**
- Explore safety assessments, leachables and the PQRI with **Allergan**
- **AstraZeneca** give key guidance on successful change controls for **design changes** and **device changes**
- Highlight the innovative solutions that **wearable devices** provide in overcoming the challenges presented by biologic drugs with **Amgen**
- Navigate **Human Factors** regulations with **AbbVie**

CHAIRS:



Dhairya Mehta, Associate Director,
Shire



Michael Selzer, Manager Combination Products
Engineering, **Regeneron**

FEATURED SPEAKERS:

- **Li-Chun Tsou**, Global Device Technical Director, **AstraZeneca**
- **Ronald Iacocca**, Research Fellow, Delivery and Device R & D, **Eli Lilly**
- **Edmond Israelski**, Director Human Factors, **AbbVie**
- **Antony Trupiano**, Head of Combination Product Development, **Shire**
- **Sudeshna Dutta Ray**, Senior Engineer Advanced Device Technology, **Amgen**
- **Stephen Barat**, Executive Director, Non-Clinical and Translational Sciences - Safety Assessment and Bioanalysis, **Allergan**
- **Tiffnay McIntire**, Human Factors Engineer, **Eli Lilly**
- **Hemal Mehta**, Manager, Global CMC-RA, Medical Devices and Combination Products, **Janssen R&D**
- **Phillip Green**, Executive Director, **Merck**
- **Kiran Singh**, Associate Director, **Sandoz**
- **Mike Price**, Senior Engineer, **Biogen**

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 25th April 2017, The Colonnade, Boston, MA, USA

WORKSHOP A

**Successful incorporation of Human Factors
in prefilled devices**

08.30 – 12.30

Leader: **Melanie Turieo**, Director,
Human Factors & Industrial Design, **Cambridge Consultants**

WORKSHOP B

**Navigating the Silicone layer; a training program, to measure
and understand siliconisation of syringes, cartridges and vials**

13.30 – 17.30

Leaders: **Oliver Valet**, Vice President, **rap.ID**
Olga Laskina, Application Scientist, **rap.ID**

Sponsored by:



www.pfsamericas.com

Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

ACADEMIC & GROUP DISCOUNTS AVAILABLE



@SMIPHARM
#smipfsusa

Pre-Filled Syringes East Coast

Day One | Wednesday 26th April 2017

08.30 Registration & Coffee

09.00 Chairman's Opening Remarks



Dhairya Mehta,
Associate Director,
Shire
Michael Selzer,
Manager, Combination Products Engineering,
Regeneron

REGULATORY UPDATES AND STRATEGY

OPENING ADDRESS:

09.10 Safety evaluation of leachables from pre-filled syringe drug products

- Background on leachable safety assessment – why and how
- Application of safety evaluation of leachables for pre-filled syringe drug products
- Utilisation of PQRI PDP best practice recommendations for small volume parenterals and how these are applied to pre-filled syringes to support biological safety



Stephen Barat, Executive Director, Non-Clinical and Translational Sciences, **Allergan**

09.50 Successful change control for patient centric drug delivery devices design and combination products post commercialisation market strategy

- When to initiate a design change or device change?
- Which changes may require post regulatory submission? All changes should be assessed as design changes, however not all device changes need to follow the full design control process
- Implementing a change – changes to correct an existing problem may have unforeseen side effects on the device



Li-Chun Tsou, Global Device Technical Director, **AstraZeneca**

10.30 Morning Coffee & Networking break sponsored by



BIOLOGICS – CHALLENGES AND OPPORTUNITIES

11.00 The role of wearable devices in overcoming the challenges of delivering large-molecule and high-volume biologics

- Latest developments - a new class of wearable on-body drug delivery devices capable of delivering higher volumes and viscosities with minimal discomfort
- The revolutionary impact of advancements with wearable injectors on biological therapy treatments
- Product uptake and acceptability – patient's view



Sudeshna Dutta Ray, Senior Engineer – Advanced Device Technology, **Amgen**

11.40 Tailoring the autoinjection with SAFELIA

- For a better patient experience and for optimised drug delivery, including high volumes and high viscosities formulation
- Safelia injection course can be adjusted to fit 'difficult' formulations delivery, reconstitution, dual injections for subcutaneous or intra-muscular injections



Isabelle Delcroix, Business Development Manager, **Nemera**

12.20 Networking Lunch Sponsored by



Letter from our Chair

Dear participants,

Pre-filled syringes have undoubtedly been one of the greatest platforms to modern medicine. Giving patients the power to handle and control their conditions and treatments has revolutionised many lives.

Though market success is determined by numerous factors; pharmaceutical work with syringes and drug delivery devices is inherently underpinned by patient centricity, and therefore bears huge responsibility to provide safe, useable and effective products. Being such a complex industry, this comes coupled with intricate challenges, opportunities and competition between pharmaceutical and device developing companies. Where there is competition, there is innovation, and we should take this opportunity to learn, develop and improve our best practise and strategy for pre-filled syringes.



Dhairya Mehta,
Associate Director
Shire

GOOD MANUFACTURING PRACTICE PART 1: DESIGN CONSIDERATIONS FOR COMBINATION PRODUCTS

13.30 Combination products: Clinical and quality considerations applicable to bridging principles

- Bridging design verification and validation for pre-filled syringe supplier changes
- Clinical bridging between Pre-filled syringes and injectors in and after Phase 3 trials – PK comparability risks
- Bridging legacy product design history files to meet 21 CFR part 4 requirements



Hemal Mehta, Manager, Global CMC-RA, Medical Devices and Combination Products, **Janssen R&D**

14.10 A comparison of the stability of protein solutions in prefilled syringes made of glass or plastic under quiescent conditions and when subjected to mild agitation

- Protein stability during long-term storage in glass vs plastic prefilled syringe systems
- The effect of autoclave vs E-beam sterilization of COP prefilled syringes on protein degradation
- Protein aggregation in prefilled syringes made of glass or plastic subjected to agitation stress
- The importance of performing a stability study in primary container systems made of glass vs plastic to determine the optimal packaging material

Lloyd Waxman, Lead Research Scientist,
West Pharmaceutical Services

14.50 PLAJEX™ with Safe 'n' Sound®: Safe delivery of biotherapeutics

William Dierick, Director Technology Development, **Terumo Pharmaceutical Solutions**
Adrien Tisserand, Global Category Manager – Parenteral & CMO, **Nemera**

15.30 Afternoon Tea & Networking break sponsored by



16.00 Pre-filled syringe selection and the impact to life cycle management of drug products

- Early decisions /stages of drug and device development - how do these systems work in parallel?
- Primary container selection and impact to life cycle management of combination products
- Moving towards auto injectors and pen devices



Antony Trupiano, Head of Combination Product Development, **Shire**

16.40 Panel Discussion: Combination products – challenges and opportunities

- On the road to patient-centric drug delivery - understanding the patient's interaction with the delivery system to be able to incorporate features which promote adherence to treatments
- Identifying the good manufacturing regulations that apply to combination products
- Technical challenges for developing and manufacturing combination products
- Regulatory hurdles in obtaining approval for pre-filled syringes and pens in human factors studies

Moderated by: Michael Selzer, Manager, Combination Products Engineering, **Regeneron**

Isabelle Delcroix, Business Development Manager, **Nemera**
Mike Price, Senior Engineer, **Biogen**



17.20 Chairman's Closing Remarks and Close of Day One



Upcoming events for the diary

- **Pre-Filled Syringes Europe**
Cophorne Tara Hotel, London UK
18th-19th January 2017
- **Pre-Filled Syringes West Coast**
Hyatt Regency Mission Bay, San Diego CA
5th - 6th June 2017

Visit www.smi-online.co.uk

MARKETING OPPORTUNITIES

Want to know how you can get involved?

Interested in promoting your services to this market?
Contact: Teri Arri SMI Marketing
on +44 (0) 20 7827 6162 or
email: tarri@smi-online.co.uk

08.30 Registration & Coffee

09.00 Chairman's Opening Remarks



Dhairya Mehta,
Associate Director,
Shire



Michael Selzer,
Manager, Combination Products Engineering,
Regeneron

GIVING YOUR DEVICE A HUMAN TOUCH

09.10 Navigating regulations surrounding Human factors

- Current regulatory climate, international and domestic
- Updates from the IEC/ISO – what does this mean for assessing and approving devices globally
- Other Human Factors standards – MHRA and AAMI – What is their impact



Edmond Israelski, Director of Human Factors, **AbbVie**

09.50 The new paradigm of digital health and connectivity – From strategy to execution with compliance

- Data collecting from patient behaviour and smart devices
- Exploring the connected drug delivery ecosystem; opportunities for feedback and monitoring
- Moving forward with smart devices



Dhairya Mehta, Associate Director, **Shire**

10.30 Morning Coffee & Networking break sponsored by

11.00 Patient centric designs for pre-filled syringes

- Understanding Human factors evaluation methods in order to achieve optimal design
- Empowering and involving patients – the role of patient-centered models in drug delivery
- New materials and modifications to existing materials – their impact on quality and reliability



Tiffney McIntire, Human Factors Engineer, **Eli Lilly**

GOOD MANUFACTURING PRACTICE OF PRE-FILLED SYRINGES – PART 2

11.40 'The use of Cyclo Olefin Polymers (COP) for syringe, vial and cartridge applications in the pharma industry

- Key properties and features of COP & its benefits for pre-filled syringe applications
- Mechanical properties after exposure to gamma, steam, EOG and cryogenic temp
- JP, US, EU Pharmacopoeia and ISO 10993 status
- Extractable/leachable test data in COP syringes with various chemicals
- Protein adsorption/aggregation study data with actual protein drugs to COP vs. glass
- Delamination study data on glass syringe



Toshiro Katayama, Senior Product Manager, **Zeon**

12.20 Networking Lunch sponsored by

13.30 Application of computer modelling in pharmaceutical packaging

- Empirical performance testing can be difficult to perform, and it can be difficult to determine the root cause of the lack of detail that can be present with empirical methods
- Modeling to minimize testing and provide greater insight for prefilled syringes
- Demonstrating how computer modelling provides greater insight into mechanical designs and material selection for primary container closure systems and the combination products that employ them
- Case study examples of the application of computer modelling in pharmaceutical packaging



Ronald Iacocca, Research Fellow, Delivery and Device R & D, **Eli Lilly**

14.10 OXYCAPT Multilayer Plastic Vial & Syringe with glass-like gas barrier for oxygen sensitive biologics

- Debating advantages of plastic syringes versus glass syringes
- How to overcome disadvantages of existing plastic syringes
- Latest studies for extractables from plastic and glass
- Minimising oxygenation and external changes through materials and development strategies



Kenchiro Usada, Researcher, **Mitsubishi Gas Chemical Company**

14.50 Criteria for pre-filled syringes CMO selection

- CMOs are a critical component of the drug product development and commercial manufacturing supply chain for many bio/pharmaceutical companies.
- The CMO must provide the specific manufacturing technologies, quality systems and regulatory support required to meet the drug product's critical quality attributes and business goals.
- Identifying and selecting the best CMO is essential to the success of any drug product program



Kiran Singh, Associate Director, **Sandoz**



Gary Mills, Associate Director Drug Development, **Tesaro**

15.30 Afternoon Tea & Networking break sponsored by

PATIENT CONCERNS FOR THE DEVELOPMENT OF PRE-FILLED SYRINGES

16.00 Challenges of Drug Delivery for Pediatric Patients: A Case Study

- How are pediatric patients different from adults?
- Should you focus on the device or the formulation?
- Pros and cons of developing solutions internally vs. outsourcing with development partners
- Commercial implications of pediatric devices



Steve Bowman, Leader, Device Center of Excellence, **Shire**

16.40 Panel Discussion: The future of parenteral drug delivery

- Addressing the need and challenges of high volume injectables:
 - Commercial opportunity and challenges
 - User considerations
 - Technologies: Wearable injectors Hand held autoinjectors & syringes etc
- Connectivity and connected devices:
 - Are they the future of parenteral drug delivery?

Moderated by: Phillip Green, Executive Director, Biologic Device Strategy, **Merck**

David Chen, Principal Scientist, Novel Drug Delivery Technologies, **Pfizer**

Sudeshna Dutta Ray, Senior Engineer – Advanced Device Technology, **Amgen**



17.20 Chairman's Closing Remarks and Close of Day Two

Official Media Partners



Supported by



Half-Day Pre-Conference Workshop A

Tuesday 25th April 2017, The Colonnade, Boston, MA, USA



Melanie Turieo,
Director, Human
Factors & Industrial Design,
Cambridge Consultants



Successful incorporation of Human Factors in prefilled devices

Workshop Overview:

This workshop will provide guidance and advice on how to successfully incorporate Human Factors into prefilled devices. Improve your understanding of Human Factors for pre-filled syringes in the context of the whole user interface; including instructional material, training and packaging. Learn to succeed in the application of Human Factors in pre-filled devices to enable delivery of high quality, market leading devices.

Reasons to attend:

- How to successfully incorporate Human Factors into device development
- Considerations for design and evaluation
- Navigating regulations and seeking approval
- Ensuring success; case study examples
- How to balance safety, usability and commercial success

About the Workshop Leader:

Melanie Turieo is a Director in Cambridge Consultants' Global MedTech division, and head of Human Centered Design. Melanie has 20 years' experience providing human factors expertise to the design and development of regulated and safety-critical items, including medical, military and consumer products. Her technical expertise has focused for the last 10 years on Human Factors Engineering in the design and development of medical products, and she has extensive experience designing and conducting user research for medical devices, especially drug delivery systems including injection and inhalation technology.

About the organisation:

Cambridge Consultants develops breakthrough products, creates IP, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, they have been helping clients turn business opportunities into commercial successes, from launching first-to-market products, entering new markets to expanding existing markets through new technologies. Their auto-injector, inhaler and injection device development programs extend from concept creation through to industrialisation, with a 'quality by design' approach and full compliance with international regulatory standards.
www.cambridgeconsultants.com

08.30 **Registration & Coffee**

09.00 **Workshop leader's opening remarks and introduction**

09.10 **Incorporating Human Factors into prefilled device development**

- What to consider when making your device Human
- Design Intent
- Tests and evaluations
- Seeking regulatory approval – what to provide to gain regulatory approval

09.40 **Case study examples - common pitfalls vs success stories**

10.10 **Discussion**

10.30 **Coffee**

11.00 **The bigger picture; Human Factors as an ecosystem consideration**

- Human Factors is not a stand-alone consideration
- Balancing safety, usability and commercial success

12.00 **Discussion**

12.30 **Workshop leader's comments and close of the workshop**

Half-Day Pre-Conference Workshop B

Tuesday 25th April 2017, The Colonnade, Boston, MA, USA



Oliver Valet,
Vice President, rap.ID
Olga Laskina,
Application Scientist, rap.ID



Navigating the silicone layer; a training program to measure and understand siliconisation of syringes, cartridges and vials

Workshop Overview:

This half day training program will teach you to put quality at the heart of your product specification and provide you with the key learning points and information needed for you to control and validate the quality parameters in a pre-filled syringe. Increasing focus on patient satisfaction, coupled with increasingly excellent homogenous silicone layers demanded by auto-injector applications and protein based formulation mean it is essential to understand and control the silicone layer in prefilled syringes.

Reasons to attend:

- Understand control of the silicone layer; application, characteristics and measurements
- Validating your product; adding value and credibility to your control and quality parameters
- Practical breakout session; test and discuss your own samples and devices

About the Workshop Leaders:

Dr Oliver Valet is the co-founder of rap.ID Inc. rap.ID's technology has combined particle isolation, imaging analysis and spectroscopic technologies, creating investigative tools for particle identification and characterization. Dr. Valet has extensive experience in foreign particulate matter testing and Root Cause Investigation. He has also worked on the development of accurate and reproducible technologies for characterizing silicone oil layer thicknesses and its distribution in parenteral packaging materials.

Dr. Olga Laskina is an Application Scientist at rap.ID Inc., specializing in developing new approaches and methodologies for analysis of active ingredients and foreign particulates in pharmaceutical products. Prior to joining rap.ID Inc., Olga did PhD research studies of chemical and physical properties of micro particles using IR and Raman spectroscopies. Olga is involved with supplier evaluation and stability studies for prefilled syringes. She has extensive experience in protein agglomeration caused by presence of silicone or tungsten and by polysorbate degradation.

13.30 **Registration & Coffee**

14.00 **Workshop leaders' opening remarks and introduction**

14.10 **Application of silicone oil and the siliconization process**

- Different methods of silicone application; spray on and baked on
- Results from static and dynamic siliconization processes
- Impact of parameters on baked silicone oil

14.40 **Silicone layer characteristics**

- From 'dust test', gravimetric extraction and force displacement measurements to image analysis and bubble counting
- Advantages and limitations of different techniques
- What do the measurement results mean?

15.10 **Discussion**

15.30 **Coffee**

16.00 **Layer explorer technology and results**

- Technology, traceability and reproducibility
- Comparison with other siliconization measurements
- Resolution and accuracy of the measurement
- Measurement results and limitations

16.30 **Case studies and investigation strategy**

- Examples of silicone thickness and distribution and stability measurement in pre-filled syringes and baked-on cartridges
- Product stability studies
- Control suppliers quality

17.00 **Protein particle investigations**

- Raman spectroscopy and image analysis of particles
- Relationship between inhomogeneous silicone oil distribution and protein aggregation
- Breakout session; How can I measure the relationship between silicone oil and protein aggregation in my product?

17.30 **Workshop leader's comments and close of Workshop**

Proudly Sponsored By:

FLUENTA OVLK



FluentaOVLK believes in a better way to manufacture liquid products that is cleaner, safer, more flexible and efficient. Our line of innovative single-use fluid path products and services are anchored by our custom molded Freedom Filler•• Kits, which include all necessary fluid path components for increased liquid filling efficiency. We utilize precision fabricated components and industry leading single-use technology to provide end-users with custom solutions that solve challenging problems associated with liquid fill/finish processing. Visit our booth to view the latest product innovations in liquid fill/finish technology, including our patented Krimploc System, Single-use Filling Needles and Freedom Filler Kits. www.ovlk.com

MW INDUSTRIES, INC



Economy Spring, a division of MW Medical Solutions. Economy Spring is a manufacturer of advanced medical device components, including highly-engineered, precision metal components and assemblies such as springs, surgical sharps, needles, laser machined tubing, staples, titanium clips, and complex assemblies. The company deploys its end-to-end product lifecycle know-how and design expertise to shorten product development time and lower costs. Economy Spring's 40-plus year track record helps deliver product reliability and performance in demanding surgical and drug delivery applications. The company is registered with the Food & Drug Administration and has ISO 9001 certified and ISO 13485 compliant quality processes. www.mw-ind.com/brands/economy-spring/

MITSUBISHI GAS CHEMICAL



Mitsubishi Gas Chemical is a leading company in the field of oxygen barrier and absorbing technologies. Based on these technologies and experiences, we have successfully developed multilayer plastic vial and syringe having excellent oxygen and water vapor barrier. The products make it possible to replace glass with plastic for injectable drugs. www.mgc.co.jp

NEMERA



Nemera is a world leader in the design, development and manufacturing of drug delivery solutions for pharmaceutical, biotechnology and generics industries. Nemera's expertise covers several modes of delivery: Parenteral, Nasal, Buccal, Auricular, Ophthalmic, Pulmonary, Dermal and Transdermal. Nemera leverages decades of experience in the parenteral device segment from full development to pure contract manufacturing, through customized solutions. Nemera developed: Safe'n'Sound®, a fully passive safety device for prefilled syringes to avoid accidental needlesticks and Safelia®, a new generation of 2-steps auto-injector for fluid and viscous formulations. www.nemera.net

OWEN MUMFORD



Owen Mumford offer an integrated design and build service from a broad base of proven self-injection and blood-sampling platform devices and intellectual property. Contact us at devicesolutions@owenmumford.co.uk www.omdevicesolutions.com

TERUMO PHARMACEUTICAL SOLUTIONS



Terumo Pharmaceutical Solutions offers the pharmaceutical and biotechnology industry unique solutions in medical technology. In addition to offering our valued products, our specialized team also provides customized and dedicated solutions designed to meet your specific requirements. www.terumo-ps.com

WEST PHARMACEUTICAL SERVICES, INC.



West is a leading manufacturer of packaging components and delivery systems. West creates products that promote the reliability and safety of the world's pharmaceutical drug supply. Headquartered in Pennsylvania, West supports customers around the globe. West's 2015 sales reflect the daily use of approximately 110 million of its products. www.westpharma.com

ZEON



Zeon Chemical's Zeonex® and Zeonor® cyclo olefin polymers (COP) allow for advanced, break-resistant syringes, vials and lyophilization containers for protein-based, peptide-based biopharmaceuticals, high viscosity drugs, and contrast media. They also offer high purity, "glass-like" transparency, sterilization, low water adsorption, and superior moldability, as well as overcome protein absorption and pH shift concerns. www.zeonex.com

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy.

Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:

Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk


Past attending organisations include:

- Actavis
- Allergan
- Aptar Pharma
- AstraZeneca
- Becton Dickinson
- Biogen
- Bristol Myers Squibb
- Eli Lilly & Co.
- Epion Pharmaceuticals
- FDA
- Genentech
- GlaxoSmithKline
- MedImmune
- Merck & Co.
- MHRA
- Otsuka US
- Pfizer
- Sanofi Aventis
- Teva
- Zoetis

And many more...

Conference attendee profile 2015/2016

Pharmaceuticals 49.15%



PRE-FILLED SYRINGES EAST COAST

Conference: Wednesday 26th & Thursday 27th April 2017, The Colonnade, Boston, MA, USA

Workshops: Tuesday 25th April 2017, The Colonnade, Boston, MA, USA

4 WAYS TO REGISTER

www.pfsamericas.com

FAX your booking form to +44 (0) 870 9090 712

PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd,

Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK

Unique Reference Number

Our Reference

LVP-203

DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Company VAT Number:

Address:

Town/City:

Post/Zip Code:

Country:

Direct Tel:

Direct Fax:

Mobile:

Switchboard:

Signature:

Date:

I agree to be bound by SMi's Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code:

Country:

Direct Tel:

Direct Fax:

VENUE The Colonnade, Boston, MA, USA

☐ Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711,

email: events@smi-online.co.uk or fax +44 (0) 870 9090 712

Terms and Conditions of Booking

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conference documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here ☐ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

EARLY BIRD DISCOUNT

- ☐ Book by the 31st January to receive \$400 off the conference price
- ☐ Book by the 28th February to receive \$200 off the conference price
- ☐ Book by the 31st March to receive \$100 off the conference price

CONFERENCE PRICES

I would like to attend: (Please tick as appropriate)

☐ Conference & 2 Workshops

☐ Conference & 1 Workshop A ☐ B ☐

☐ Conference only

☐ 2 Workshops

☐ 1 Workshop only A ☐ B ☐

Fee

\$2897.00

\$2398.00

\$1899.00

\$998.00

\$499.00

PROMOTIONAL LITERATURE DISTRIBUTION

☐ Distribution of your company's promotional

literature to all conference attendees

\$1598

+ VAT \$1917.60

The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.

DOCUMENTATION

I cannot attend but would like to purchase access to the following

Document Portal/paper copy documentation	Price	Total
<input type="checkbox"/> Access to the conference documentation on the Document Portal	\$624.00 + VAT	\$748.80
<input type="checkbox"/> The Conference Presentations – paper copy (or only \$375 if ordered with the Document Portal)	\$624.00 -	\$624.00

PAYMENT

Payment must be made to **SMi Group Ltd**, and received before the event, by one of the following methods **quoting reference P-203 and the delegate's name**. Bookings made within 7 days of the event require payment on booking, methods of payment:

A/C Name **SMI GROUP LTD** Sort Code **300009**,

Account Number **11775391** CCY **USD**

☐ **Wire Transfer** Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU

IBAN **GB75LOYD30000911775391**

BIC **LOYDGB21013**

☐ **Cheque** We can only accept cheques in US dollars.

☐ **Credit Card** ☐ Visa ☐ MasterCard ☐ American Express

All credit card payments will be subject to standard credit card charges.

Card No:

Valid From / / Expiry Date / /

CVV Number 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder's Name:

Signature:

Date:

I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (If different from above):

VAT

VAT at 20% is charged on document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here.